Hangzhou Tigermed Consulting Co.,Ltd.(300347),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

300347 Hangzhou Tigermed Consulting Co.,Ltd.

Closed 01-05 15:00:00

59.17

+2.47

+4.36%

High59.88	Low56.22	Vol14.24M
Open56.80	D1 Closing56.70	Amplitude6.46%
Mkt Cap50.95B	Tradable Cap33.49B	Total Shares861.00M
T/O834.00M	T/O Rate2.52%	Tradable Shares566.00M
P/B2.31	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"300347","market":"SZ","secType":"STK","nameCN":"Hangzhou Tigermed Consulting Co.,Ltd.","latestPrice":59.17,"timestamp":1767596592000,"preClose":56.7,"halted":0,"volume":14236591,"delay":0,"changeRate":0.0436,"floatShares":566000000,"shares":861000000,"eps":0.711,"marketStatus":"Closed","change":2.47,"latestTime":"01-05 15:00:00","open":56.8,"high":59.88,"low":56.22,"amount":834000000,"amplitude":0.0646,"askPrice":59.18,"askSize":12,"bidPrice":59.17,"bidSize":32,"shortable":0,"etf":0,"ttmEps":0.711,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1767663000000},"marketStatusCode":5,"adr":0,"adjPreClose":56.7,"symbolType":"stock","openAndCloseTimeList":[[1767576600000,1767583800000],[1767589200000,1767596400000]],"highLimit":62.37,"lowLimit":51.03,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":861026050,"isCdr":false,"pbRate":2.31,"roa":"--","peRate":83.220816,"roe":"4.89%","epsLYR":0.47,"committee":-0.652778,"marketValue":50947000000,"turnoverRate":0.0251,"status":0,"hkstockBrief":{"symbol":"03347","market":"HK","secType":"STK","nameCN":"TIGERMED","latestPrice":45.22,"timestamp":1767600534006,"preClose":42.44,"halted":0,"volume":2790200,"delay":0,"premium":"-31.43"},"floatMarketCap":33503000000},"requestUrl":"/m/hq/s/300347/wiki","defaultTab":"wiki","newsList":[{"id":"1191006180","title":"Delisted from Shenzhen 100, Market Cap Evaporates by 100 Billion: How Can Tigermed Overcome Its \"Investment Dependence\"?","url":"https://stock-news.laohu8.com/highlight/detail?id=1191006180","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191006180?lang=en_us&edition=fundamental","pubTime":"2025-12-25 17:41","pubTimestamp":1766655706,"startTime":"0","endTime":"0","summary":"While the CRO industry is experiencing a collective recovery due to \"high-priced demand for monkeys,\" with the sector rising over 40% year-to-date, the former industry benchmark Tigermed (300347) has...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0174","BK1583","161227","BK0077","LU1146622755.USD","BK0028","BK1576","300347","BK0216","03347","BK1141","399330","LU1820825898.SGD"],"gpt_icon":0},{"id":"1150111585","title":"TIGERMED Removed from SZSE 100 Index After Losing Over 100 Billion in Market Value","url":"https://stock-news.laohu8.com/highlight/detail?id=1150111585","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150111585?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:10","pubTimestamp":1766059823,"startTime":"0","endTime":"0","summary":"On December 15, TIGERMED was removed from the SZSE 100 Index, ending its six-year tenure in the benchmark. Despite reporting a 20.88% year-on-year increase in net profit for the first three quarters...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0174","BK1576","BK0028","161227","300347","BK0077","BK0216","BK1141","399330","03347","LU1146622755.USD","BK1583","LU1820825898.SGD"],"gpt_icon":0},{"id":"2590571518","title":"Frontage Holdings Corporation Announces Date for Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2590571518","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590571518?lang=en_us&edition=fundamental","pubTime":"2025-12-12 16:40","pubTimestamp":1765528816,"startTime":"0","endTime":"0","summary":"Frontage Holdings Corporation has announced that it will hold an extraordinary general meeting on January 7, 2026, at Building 2, No. 1227 Zhangheng Road, Zhangjiang Hi-Tech Park, Shanghai, China. Shareholders will consider and, if thought fit, transact the proposed resolution as an ordinary resolution of the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Frontage Holdings Corporation published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 12, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDLbBhQCs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01521","BK0011","BK0273","BK1576","300347","BK0184","BK0075","BK0190","BK0028","BK0020","BK0012","600895","BK1583","BK0059","BK0077","BK0183","BK0053","BK0174","BK0188","LU1146622755.USD","BK0099","BK1141","BK0216","LU1820825898.SGD"],"gpt_icon":0},{"id":"2590579081","title":"Frontage Holdings Corporation to Vote on Share Transfer Agreement and Acquisition at Upcoming Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2590579081","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590579081?lang=en_us&edition=fundamental","pubTime":"2025-12-12 16:31","pubTimestamp":1765528314,"startTime":"0","endTime":"0","summary":"Frontage Holdings Corporation will hold an extraordinary general meeting on January 7, 2026, where shareholders will vote on a proposal to approve the acquisition of the entire issued share capital of the target company through a Share Transfer Agreement. The Independent Board Committee and its financial adviser have recommended that shareholders vote in favor of the proposal, considering the terms fair, reasonable, and in the interests of the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Frontage Holdings Corporation published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 12, 2025, and is solely responsible for the informa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL1hkzGN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","01521","BK0216","BK0174","BK0028","BK1576","LU1146622755.USD","BK1583","LU1820825898.SGD","300347","BK0077"],"gpt_icon":0},{"id":"1141702662","title":"Xingquan Global Fund Reduces Stake in TIGERMED (03347) by 216,800 Shares at HK$37.7 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1141702662","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141702662?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:20","pubTimestamp":1764847216,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, on December 3, Xingquan Global Fund Management Co., Ltd. reduced its stake in TIGERMED (03347) by 216,800 shares at HK$37.7041 per...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1576","BK0216","BK0028","LU1146622755.USD","LU1820825898.SGD","BK0174","300347","BK0077","03347","BK1141","BK1583"],"gpt_icon":0},{"id":"1164114824","title":"JPMorgan Reduces Stake in TIGERMED (03347) by Approximately 831,200 Shares at Average Price of HK$39.82 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1164114824","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164114824?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:48","pubTimestamp":1764593311,"startTime":"0","endTime":"0","summary":"Latest data from the Hong Kong Stock Exchange reveals that on November 25, JPMorgan reduced its holdings in TIGERMED (03347) by 831,247 shares at an average price of HK$39.8240 per share, totaling...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2505996681.GBP","BK4585","LU1548497426.USD","LU1244550221.USD","LU2462157665.USD","IE00BN8TJ469.HKD","LU0211328371.USD","LU0868494708.USD","LU0323591593.USD","IE00BBT3K403.USD","BK1583","LU2237443465.HKD","LU0976567544.SGD","LU0106831901.USD","LU1629891620.HKD","LU2023250330.USD","LU2211815571.USD","LU2417539215.USD","LU2054465674.USD","LU1670627923.USD","LU2756315664.SGD","LU1145028129.USD","LU0265550946.USD","BK1576","IE00BHPRN162.USD","LU2106854487.HKD","LU0320765489.SGD","LU1720051017.SGD","LU1988902786.USD","IE0034235295.USD","LU0964807845.USD","LU1496350171.SGD","LU2430703095.HKD","IE00BFXG1179.USD","LU0203345920.USD","LU1280957306.USD","LU1363072403.SGD","IE00BDRTCR15.USD","LU0265550359.USD","LU0345769631.USD","LU0215105999.USD","LU1084165304.USD","LU0345770993.USD","BK4566","LU1119994496.HKD","LU0943347566.SGD","LU2746668974.SGD","IE00BKDWB100.SGD","LU2237443622.USD","LU0942090050.USD","LU2023250504.SGD","LU0149725797.USD","IE00BWXC8680.SGD","SG9999002232.USD","IE00BYXW3230.USD","LU0238689110.USD","LU1720051108.HKD","LU0787776722.HKD","IE00BLSP4452.SGD","LU2236285917.USD","LU2237443978.SGD","LU1116320737.USD","LU0211326839.USD","LU1551013342.USD","LU2237443382.USD","LU0211331839.USD","IE00B3S45H60.SGD","LU1820825898.SGD","LU1366192091.USD","IE00BDCRKT87.USD","LU0640476718.USD","03347","IE000M9KFDE8.USD","LU2264538146.SGD","LU2746668461.USD","IE00BJTD4N35.SGD","LU1496350502.SGD","IE0034235303.USD","LU2592432038.USD","LU0689472784.USD","LU0211326755.USD","LU1894683348.USD","IE00BZ1G4Q59.USD","LU0820562030.AUD","LU1974910355.USD","JPM","LU1551013425.SGD","LU0345769128.USD","LU0256863811.USD","IE00BJLML261.HKD","LU0006306889.USD","LU2456880835.USD","LU2552382132.HKD","BK4588","LU0820561818.USD","IE00BJTD4V19.USD","LU0683600562.USD","IE00B1XK9C88.USD","BK4504","LU0868494617.USD","LU2237443895.HKD","LU2023250843.SGD","LU0820561909.HKD","LU1244550494.USD","LU2242649171.HKD","LU1244550577.SGD","LU2505996509.AUD","IE00B775SV38.USD","LU2357305700.SGD","BK0028","LU1668664300.SGD","LU1267930490.SGD","LU1914381329.SGD","LU0234572021.USD","LU0267386448.USD","LU0345770308.USD","LU2381873111.SGD","BK4581","LU0170899867.USD","LU1670628061.USD","LU0203347892.USD","LU1116320901.HKD","BK0216","LU0048584097.USD","BK0077","BK4534","LU0070302665.USD","LU2213496289.HKD","LU0106261372.USD","SG9999002224.SGD","LU0320765646.SGD","IE0034235188.USD","LU1261432733.SGD","LU1162221912.USD","LU2237443549.SGD","LU0211327993.USD","BK1141","BK4516","LU0251132253.USD","LU2552382058.USD","BK4533","BK4550","LU1032466523.USD","300347","LU2756315318.SGD","LU0971096721.USD","LU2552382215.SGD","LU2430703178.SGD","BK4207","LU0417517546.SGD","LU1917777945.USD","LU0208291251.USD","LU0882574139.USD","LU0310799852.SGD","LU0496365809.HKD","LU1064131342.USD","LU1146622755.USD","IE00BLSP4239.USD","IE00BKVL7J92.USD","BK0174","LU2430703251.USD","LU1894683264.USD","IE00B1BXHZ80.USD"],"gpt_icon":0},{"id":"1183732595","title":"JPMorgan Increases Stake in Tigermed (03347) by Approximately 501,500 Shares at HK$38.95 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1183732595","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183732595?lang=en_us&edition=fundamental","pubTime":"2025-11-27 19:20","pubTimestamp":1764242437,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, on November 24, JPMorgan increased its stake in Tigermed (03347) by 501,547 shares at an average price of HK$38.9488 per share,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2462157665.USD","LU1496350171.SGD","LU1668664300.SGD","LU1894683264.USD","IE00BKVL7J92.USD","LU2023250330.USD","LU2756315664.SGD","LU2023250504.SGD","IE00B1XK9C88.USD","LU2237443895.HKD","LU0787776722.HKD","LU2746668461.USD","LU0323591593.USD","LU1244550221.USD","LU1670627923.USD","LU1363072403.SGD","LU0208291251.USD","LU0417517546.SGD","LU0265550359.USD","IE0034235188.USD","LU2242649171.HKD","LU0211327993.USD","LU2237443465.HKD","03347","LU0345770308.USD","LU0211326839.USD","LU0265550946.USD","LU2264538146.SGD","IE0034235303.USD","LU2430703095.HKD","LU1974910355.USD","IE00B775SV38.USD","LU0320765489.SGD","BK0028","IE00BZ1G4Q59.USD","LU2213496289.HKD","LU1551013425.SGD","LU1720051017.SGD","JPM","LU0942090050.USD","BK4533","LU0868494617.USD","LU1366192091.USD","LU1917777945.USD","LU0238689110.USD","LU0496365809.HKD","LU2357305700.SGD","LU2430703178.SGD","LU2381873111.SGD","LU0234572021.USD","BK0077","LU1267930490.SGD","LU2505996509.AUD","LU0006306889.USD","LU2505996681.GBP","LU0211326755.USD","LU1894683348.USD","LU1820825898.SGD","LU0170899867.USD","BK4550","LU2237443622.USD","IE00BJTD4V19.USD","LU0203347892.USD","LU1244550494.USD","LU0048584097.USD","LU2430703251.USD","LU2417539215.USD","LU1119994496.HKD","LU1244550577.SGD","LU1146622755.USD","LU1145028129.USD","BK4585","LU0106261372.USD","LU0683600562.USD","LU1670628061.USD","LU1280957306.USD","IE00BJTD4N35.SGD","LU0215105999.USD","LU0345769128.USD","LU2236285917.USD","IE00B3S45H60.SGD","LU1162221912.USD","BK4516","SG9999002224.SGD","LU0211331839.USD","BK4207","LU2237443978.SGD","LU0267386448.USD","LU2756315318.SGD","IE00BLSP4239.USD","LU2211815571.USD","LU2237443382.USD","BK1583","LU0070302665.USD","LU0256863811.USD","LU0251132253.USD","300347","LU2456880835.USD","LU0640476718.USD","LU2023250843.SGD","LU1988902786.USD","IE00BYXW3230.USD","IE00BDCRKT87.USD","LU2237443549.SGD","LU0203345920.USD","IE00BWXC8680.SGD","LU0106831901.USD","LU0964807845.USD","BK1141","LU1064131342.USD","IE00BBT3K403.USD","LU0882574139.USD","BK0216","IE000M9KFDE8.USD","IE00B1BXHZ80.USD","IE00BHPRN162.USD","LU0149725797.USD","LU2552382132.HKD","LU0345770993.USD","LU2592432038.USD","BK1576","LU0310799852.SGD","IE00BN8TJ469.HKD","LU0320765646.SGD","BK0174","LU1914381329.SGD","LU0211328371.USD","IE00BLSP4452.SGD","LU0689472784.USD","BK4588","BK4534","LU0868494708.USD","BK4504","SG9999002232.USD","LU1116320737.USD","LU1032466523.USD","LU0976567544.SGD","IE00BDRTCR15.USD","IE00BFXG1179.USD","LU2106854487.HKD","LU1496350502.SGD","LU1261432733.SGD","LU2054465674.USD","LU1720051108.HKD","BK4566","IE0034235295.USD","IE00BKDWB100.SGD","LU0820561909.HKD","LU1551013342.USD","LU0345769631.USD","LU2552382058.USD","IE00BJLML261.HKD","LU0820561818.USD","LU0971096721.USD","LU1548497426.USD","LU1629891620.HKD","BK4581","LU1116320901.HKD","LU2552382215.SGD","LU1084165304.USD","LU0943347566.SGD","LU2746668974.SGD","LU0820562030.AUD"],"gpt_icon":0},{"id":"1110073939","title":"TIGERMED (03347) Rises Over 4% as Q3 Revenue Shows Significant Improvement with Double-Digit Growth in SMO New Orders","url":"https://stock-news.laohu8.com/highlight/detail?id=1110073939","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110073939?lang=en_us&edition=fundamental","pubTime":"2025-11-10 10:18","pubTimestamp":1762741093,"startTime":"0","endTime":"0","summary":"TIGERMED (03347) surged over 4%, reaching HK$43.9 by the time of writing, with a trading volume of HK$20.72 million. The company recently released its Q3 2025 financial report, showing total revenue...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1820825898.SGD","LU1146622755.USD","03347","BK0216","BK1576","BK0077","BK1583","BK0028","BK1141","BK0174","300347"],"gpt_icon":0},{"id":"1115325367","title":"CLSA Maintains Outperform Rating on TIGERMED (03347) Amid Q3 Moderate Recovery","url":"https://stock-news.laohu8.com/highlight/detail?id=1115325367","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115325367?lang=en_us&edition=fundamental","pubTime":"2025-10-30 17:40","pubTimestamp":1761817259,"startTime":"0","endTime":"0","summary":"CLSA released a research report stating that TIGERMED's (03347) Q3 performance reflects a moderate recovery in its business. While margins remain under pressure, the firm expects a potential rebound...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1820825898.SGD","03347","300347","BK1141","BK0028","BK0174","BK1576","BK1583","LU1146622755.USD","BK0077","BK0216"],"gpt_icon":0},{"id":"1195677971","title":"TIGERMED (03347) Reports Q3 Results: Net Profit Attributable to Shareholders Rises 25.45% YoY to RMB1.02 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1195677971","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195677971?lang=en_us&edition=fundamental","pubTime":"2025-10-28 16:44","pubTimestamp":1761641058,"startTime":"0","endTime":"0","summary":"TIGERMED (03347) announced its third-quarter results for 2025. The group recorded operating revenue of RMB5.026 billion in the first three quarters, representing a slight decrease of 0.82%...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0174","BK1576","BK0077","300347","LU1820825898.SGD","LU1146622755.USD","BK0216","BK0028","BK1583","03347","BK1141"],"gpt_icon":0},{"id":"1142491582","title":"E Fund Reduces Stake in TIGERMED (03347) by 429,800 Shares at Approximately HKD 42.78 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1142491582","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142491582?lang=en_us&edition=fundamental","pubTime":"2025-10-24 19:48","pubTimestamp":1761306501,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, on October 21, E Fund Management Co., Ltd. reduced its stake in TIGERMED (03347) by 429,800 shares, at a price of HKD 42.779 per share,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0174","BK1576","BK0028","300347","BK0077","BK0216","BK1141","03347","LU1146622755.USD","BK1583","LU1820825898.SGD"],"gpt_icon":0},{"id":"1104202899","title":"EFUND Investment Management Increases Stake in TIGERMED (03347) by 573,100 Shares at Approximately HK$42.09 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1104202899","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104202899?lang=en_us&edition=fundamental","pubTime":"2025-10-16 19:16","pubTimestamp":1760613396,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, on October 13, EFUND Investment Management Co., Ltd. increased its holding in TIGERMED (03347) by 573,100 shares at a price of...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0077","BK0216","BK1583","BK1141","BK1576","LU1820825898.SGD","BK0174","BK0028","300347","LU1146622755.USD","03347"],"gpt_icon":0},{"id":"1172110626","title":"Goldman Sachs Initiates Coverage on TIGERMED (03347) H-Shares with \"Buy\" Rating, HK$62.1 Target Price","url":"https://stock-news.laohu8.com/highlight/detail?id=1172110626","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172110626?lang=en_us&edition=fundamental","pubTime":"2025-10-14 15:14","pubTimestamp":1760426065,"startTime":"0","endTime":"0","summary":"Goldman Sachs issued a research report upgrading TIGERMED A-shares (300347.SZ) from \"Neutral\" to \"Buy\" with a target price increase from RMB 62.1 to RMB 77.1. The firm also initiated coverage on...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300347","BK1576","BK0028","BK1583","LU1146622755.USD","BK0174","03347","BK0077","BK0216","BK1141","LU1820825898.SGD"],"gpt_icon":0},{"id":"2571949870","title":"Onco-Innovations Launches Preclinical Development of PNKP Inhibitor with Validated Analytical Methods by Nucro-Technics","url":"https://stock-news.laohu8.com/highlight/detail?id=2571949870","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571949870?lang=en_us&edition=fundamental","pubTime":"2025-09-29 12:00","pubTimestamp":1759118415,"startTime":"0","endTime":"0","summary":"Onco-Innovations Ltd. has announced the initiation of preclinical and analytical development for its proprietary Polynucleotide Kinase Phosphatase  inhibitor technology. In collaboration with Nucro-Technics Inc., the company has begun laboratory work to develop and validate advanced analytical methods, using liquid chromatography-mass spectrometry , to measure the PNKP inhibitor in preclinical samples and drug formulations. These methods are essential for regulatory submissions and will underpin future studies, including formal toxicology and pharmacokinetics assessments. The results represent a key step in Onco-Innovations' IND-enabling program and have not yet been presented, as the validated methods will serve as the foundation for upcoming research and regulatory filings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informationa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDL8y07fQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0077","300347","LU1146622755.USD","BK0174","BK0216","LU1820825898.SGD"],"gpt_icon":0},{"id":"1154014124","title":"TIGERMED Rises Over 5% in Early Trading as Overseas Clinical Operations Show Strong Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1154014124","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154014124?lang=en_us&edition=fundamental","pubTime":"2025-09-24 11:01","pubTimestamp":1758682895,"startTime":"0","endTime":"0","summary":"TIGERMED (03347) surged over 6% during trading, and as of press time, the stock price gained 5.39% to HK$47.68, with turnover reaching HK$88.91 million. CITIC Securities Investment Banking released a...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03347","BK1141","BK1576","LU1146622755.USD","LU1820825898.SGD","BK0077","BK0028","BK1583","300347","BK0216","BK0174"],"gpt_icon":0},{"id":"1120233979","title":"E Fund Management Reduces TIGERMED (03347) Holdings by 876,900 Shares at Approximately HK$46.57 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1120233979","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120233979?lang=en_us&edition=fundamental","pubTime":"2025-09-22 19:56","pubTimestamp":1758542200,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, E Fund Management reduced its holdings in TIGERMED (03347) by 876,900 shares on September 17, at a price of HK$46.5701 per share, with...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1576","BK0174","03347","BK0028","BK1141","BK0077","LU1820825898.SGD","300347","BK0216","BK1583","LU1146622755.USD"],"gpt_icon":0},{"id":"1163665489","title":"E Fund Management Reduces Stake in TIGERMED (03347) by 4.17 Million Shares at HK$44.34 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1163665489","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163665489?lang=en_us&edition=fundamental","pubTime":"2025-09-16 19:10","pubTimestamp":1758021021,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, E Fund Management reduced its holdings in TIGERMED (03347) by 4.1744 million shares on September 11, at a price of HK$44.3362 per...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","LU1820825898.SGD","BK1141","BK0077","BK0174","LU1146622755.USD","03347","BK0028","BK0216","BK1576","300347"],"gpt_icon":0},{"id":"1154530061","title":"TIGERMED to Hold First Extraordinary General Meeting of 2025 on September 29","url":"https://stock-news.laohu8.com/highlight/detail?id=1154530061","media":"Deep News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154530061?lang=en_us&edition=fundamental","pubTime":"2025-09-08 20:20","pubTimestamp":1757334023,"startTime":"0","endTime":"0","summary":"On the evening of September 8, TIGERMED announced that the company will convene its first extraordinary general meeting of 2025 on September 29, 2025. The shareholders' meeting will deliberate on...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1146622755.USD","LU1820825898.SGD","BK1576","BK1141","BK1583","BK0174","BK0028","BK0077","BK0216","03347","300347"],"gpt_icon":0},{"id":"1180947745","title":"JPMorgan Increases Holdings in TIGERMED (03347) by 343,700 Shares at Approximately HK$46.98 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1180947745","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180947745?lang=en_us&edition=fundamental","pubTime":"2025-09-04 19:00","pubTimestamp":1756983625,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, JPMorgan increased its holdings in TIGERMED (03347) by 343,700 shares on August 29th, at a price of HK$46.9778 per share, with a total...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0238689110.USD","LU1551013342.USD","LU1820825898.SGD","SG9999002224.SGD","LU1244550221.USD","LU2552382058.USD","LU0149725797.USD","LU2756315318.SGD","LU0345770993.USD","LU2023250330.USD","BK1583","LU0323591593.USD","LU2237443895.HKD","LU1894683348.USD","BK4588","IE0034235295.USD","LU0234572021.USD","LU0496365809.HKD","LU1974910355.USD","LU2106854487.HKD","LU0320765646.SGD","LU0942090050.USD","LU2242649171.HKD","BK4550","BK4516","LU0976567544.SGD","LU0048584097.USD","LU2430703095.HKD","LU0689472784.USD","LU0215105999.USD","LU0208291251.USD","BK1141","LU2505996509.AUD","LU1366192091.USD","LU0106831901.USD","LU0787776722.HKD","IE00BZ1G4Q59.USD","LU2213496289.HKD","LU0868494617.USD","BK4585","LU2237443549.SGD","LU1670628061.USD","LU0256863811.USD","IE00B1XK9C88.USD","LU0106261372.USD","LU2237443382.USD","LU2417539215.USD","LU2552382215.SGD","LU2746668461.USD","IE0034235303.USD","IE00BDCRKT87.USD","LU2054465674.USD","IE00BFXG1179.USD","LU1988902786.USD","03347","LU1548497426.USD","LU1244550494.USD","LU2023250843.SGD","LU1917777945.USD","LU2237443622.USD","LU0203345920.USD","LU1894683264.USD","SG9999002232.USD","LU0310799852.SGD","LU2264538146.SGD","LU0320765489.SGD","LU1363072403.SGD","LU2430703251.USD","LU1668664300.SGD","LU1162221912.USD","LU2236285917.USD","LU2430703178.SGD","LU1064131342.USD","IE00BYXW3230.USD","LU0211326755.USD","LU0345770308.USD","LU0345769128.USD","IE00BKVL7J92.USD","LU1261432733.SGD","LU0251132253.USD","LU0683600562.USD","LU2237443978.SGD","BK0216","LU2592432038.USD","LU0211326839.USD","BK4581","LU1267930490.SGD","BK0174","LU0868494708.USD","LU1119994496.HKD","LU1496350171.SGD","LU0170899867.USD","IE00BJLML261.HKD","BK4504","BK0028","LU1551013425.SGD","LU0640476718.USD","IE00BBT3K403.USD","LU0417517546.SGD","LU2023250504.SGD","300347","IE00BWXC8680.SGD","LU0820562030.AUD","LU0820561909.HKD","LU1670627923.USD","LU0211328371.USD","LU1084165304.USD","BK4534","LU1145028129.USD","LU2552382132.HKD","LU0820561818.USD","IE00BHPRN162.USD","LU1720051017.SGD","LU0211327993.USD","LU2456880835.USD","LU0345769631.USD","LU1720051108.HKD","LU0943347566.SGD","LU0971096721.USD","LU1146622755.USD","LU1244550577.SGD","LU2505996681.GBP","LU1496350502.SGD","IE00BJTD4N35.SGD","IE0034235188.USD","LU0070302665.USD","BK4207","BK1576","IE00BJTD4V19.USD","LU0211331839.USD","BK4533","LU0267386448.USD","LU0964807845.USD","LU2357305700.SGD","IE00BLSP4452.SGD","LU0006306889.USD","LU2462157665.USD","LU1914381329.SGD","LU2756315664.SGD","IE00B3S45H60.SGD","IE00BKDWB100.SGD","IE00BN8TJ469.HKD","BK0077","LU1280957306.USD","LU2237443465.HKD","LU1032466523.USD","LU1629891620.HKD","LU2746668974.SGD","LU0203347892.USD","IE00B1BXHZ80.USD","BK4566","IE00BLSP4239.USD","IE00BDRTCR15.USD","IE000M9KFDE8.USD","IE00B775SV38.USD","LU0882574139.USD"],"gpt_icon":0},{"id":"1158170257","title":"BOC International Raises TIGERMED (03347) Target Price to HK$51, Maintains \"BUY\" Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1158170257","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158170257?lang=en_us&edition=fundamental","pubTime":"2025-09-03 17:24","pubTimestamp":1756891473,"startTime":"0","endTime":"0","summary":"BOC International released a research report stating that TIGERMED's (03347) first-half performance reflects the ongoing challenges facing China's biotechnology industry, where weak demand and...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK0028","BK0216","BK1576","LU1820825898.SGD","BK0174","300347","BK1141","LU1146622755.USD","03347","BK0077"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2012-08-17","address":"浙江省杭州市滨江区西兴街道聚工路19号8幢20层2001-2010室","stockEarnings":[{"period":"1week","weight":0.0594},{"period":"1month","weight":0.1168},{"period":"3month","weight":-0.0224},{"period":"6month","weight":0.0547},{"period":"1year","weight":0.0441},{"period":"ytd","weight":0.0441}],"companyName":"杭州泰格医药科技股份有限公司","boardCode":"AI0073","perCapita":"--","boardName":"研究和试验发展","registeredCapital":"86102万元","compareEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.014},{"period":"3month","weight":0.0222},{"period":"6month","weight":0.143},{"period":"1year","weight":0.1841},{"period":"ytd","weight":0.1841}],"survey":"　　杭州泰格医药科技股份有限公司的主营业务是为新药研发提供临床试验全过程专业服务的合同研究组织（CRO），为全球医药和医疗器械创新企业提供全面而综合的临床研究解决方案。公司的主要产品是临床运营、临床药理、注册与法规事务、科学事务、医学翻译、药物警戒、真实世界研究、第三方稽查与培训、数据管理及统计分析、临床试验现场管理、受试者招募、医学影像以及实验室。","serverTime":1767619473780,"listedPrice":37.88,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Hangzhou Tigermed Consulting Co.,Ltd.(300347),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Hangzhou Tigermed Consulting Co.,Ltd.(300347) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Hangzhou Tigermed Consulting Co.,Ltd.,300347,Hangzhou Tigermed Consulting Co.,Ltd.股票,Hangzhou Tigermed Consulting Co.,Ltd.股票老虎,Hangzhou Tigermed Consulting Co.,Ltd.股票老虎国际,Hangzhou Tigermed Consulting Co.,Ltd.行情,Hangzhou Tigermed Consulting Co.,Ltd.股票行情,Hangzhou Tigermed Consulting Co.,Ltd.股价,Hangzhou Tigermed Consulting Co.,Ltd.股市,Hangzhou Tigermed Consulting Co.,Ltd.股票价格,Hangzhou Tigermed Consulting Co.,Ltd.股票交易,Hangzhou Tigermed Consulting Co.,Ltd.股票购买,Hangzhou Tigermed Consulting Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Hangzhou Tigermed Consulting Co.,Ltd.(300347),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Hangzhou Tigermed Consulting Co.,Ltd.(300347) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction